## 2 Materials and Methods
Currently, according to several authors, medical-genetic consultation is one of the most widespread and effective methods for diagnosing and preventing hereditary diseases, including fetal pathologies occurring during the perinatal period. Medical-genetic consultation is considered the cornerstone that connects several aspects of medicine, genetics, psychology, education, and social work. During the medical-genetic consultations of families at high risk for cerebral pathology, we gathered information regarding their family history, which allowed us to construct a pedigree for each family in the risk group. These data, including the disease history, family history, socio-economic conditions, demographics, and consanguinity (the degree of kinship between parents), were collected during conversations with the parents, relatives, and caregivers of the sick children. The methods used in the medical-genetic consultations included gathering anamnesis data, constructing the family pedigree of families with sick children, the psychoneurological examination of subjects based on clinical syndromes, prenatal diagnostics, laboratory methods (cytogenetic, molecular-genetic, biochemical), screening, and ultrasound (USG). Prenatal diagnostics play an essential role in preventing the birth of children with fetal pathologies, as they enabled the forecasting of a child's health in high-genetic-risk groups for perinatal neurological pathologies. The second study (clinical-immunoenzymatic), a non-randomized prospective prognostic study, was conducted at the Pediatric Neurology Clinic of the Department of Pediatrics of USMF Nicolae Testermitanu, in the psychoneurology departments of the MHCI IMC and MHCI HCM nr. 1, between 2017 and 2020. The study included the immunoenzymatic testing of biomarkers such as IL-6, the S100B protein, VEGF, CD105 (endoglin), CNTF, and APAs during the acute phase of the disease, as well as the testing of VEGF and S100B protein levels six months after AIS. To achieve this goal, we selected 69 children, 8 of whom did not meet the inclusion criteria: 5 refused to participate, and 3 had other reasons. The study ultimately included 53 children with AIS. We estimated the following core components: correlations between the serum levels of neuroinflammatory biomarkers (BN) (IL-6, S100B protein, VEGF, CD105 endoglin, CNTF, and APA), as well as correlations with scores on scales evaluating the degree of patient suffering, imaging and electrophysiological results, and neurological outcomes in children post-AIS. The BN research was made possible by the project \"Evaluation of the incidence, prevalence, risk factors, clinical aspects, neuroimaging, neurophysiological aspects, and neurotrophic recovery of cerebrovascular accidents in children\", part of the state program \"Systemogenesis of risk factors, optimization of healthcare services, sustainable evaluation, and mathematical modeling of stroke\", taking into account the costs and methodological difficulties of the method (rarely used for scientific purposes). The project was carried out in the Department of Pediatrics at USMF Nicolae Testermitanu. The parents of the children included in the study were informed about the scientific purpose of the research, and informed consent was obtained for their participation. All relevant parties, including the heads of clinics, heads of neurology departments, and pediatric neurologists, were informed about the necessary examinations. We collaborated with the Biochemical Diagnostic Laboratory at USMF Nicolae Testermitanu to perform immunological tests while maintaining the confidentiality of the data. The data on the total number and characteristics of the patients included in the study, according to the age criteria, are presented in detail and systematically in Table 1.  
In the current research, a questionnaire developed for this study was applied to determine and analyze the risk factors, life history, disease history, and the clinical and paralclinical profile of IS in children.